369 related articles for article (PubMed ID: 11332289)
1. Use of ML dipstick as a tool to classify leprosy patients.
Buhrer-Sekula S; Sarno EN; Oskam L; Koop S; Wichers I; Nery JA; Vieira LM; de Matos HJ; Faber WR; Klatser PR
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):456-63. PubMed ID: 11332289
[TBL] [Abstract][Full Text] [Related]
2. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients.
Bührer-Sékula S; Visschedijk J; Grossi MA; Dhakal KP; Namadi AU; Klatser PR; Oskam L
Lepr Rev; 2007 Mar; 78(1):70-9. PubMed ID: 17518099
[TBL] [Abstract][Full Text] [Related]
3. Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy--a comparison of methods based mainly on skin smears as opposed to clinical methods--alternative clinical methods for classification of patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):292-303. PubMed ID: 2071986
[TBL] [Abstract][Full Text] [Related]
4. The additional benefit of the ML Flow test to classify leprosy patients.
Bührer-Sékula S; Illarramendi X; Teles RB; Penna ML; Nery JA; Sales AM; Oskam L; Sampaio EP; Sarno EN
Acta Trop; 2009 Aug; 111(2):172-6. PubMed ID: 19393609
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant serine-rich 45-kDa antigen (ML0411) for detection of antibodies in leprosy patients.
Parkash O; Kumar A; Nigam A; Franken KL; Ottenhoff TH
Scand J Immunol; 2006 Oct; 64(4):450-5. PubMed ID: 16970689
[TBL] [Abstract][Full Text] [Related]
6. Classification of leprosy into multibacillary and paucibacillary groups: an analysis.
Parkash O
FEMS Immunol Med Microbiol; 2009 Jan; 55(1):1-5. PubMed ID: 19040664
[TBL] [Abstract][Full Text] [Related]
7. Dipstick assay to identify leprosy patients who have an increased risk of relapse.
Bührer-Sékula S; Cunha MG; Foss NT; Oskam L; Faber WR; Klatser PR
Trop Med Int Health; 2001 Apr; 6(4):317-23. PubMed ID: 11348523
[TBL] [Abstract][Full Text] [Related]
8. A study on a possibility of predicting early relapse in leprosy using a ND-O-BSA based ELISA.
Wu Q; Yin Y; Zhang L; Chen X; Yu Y; Li Z; Yu H; Lu C; Feng S; Li X; Huo W; Ye G
Int J Lepr Other Mycobact Dis; 2002 Mar; 70(1):1-8. PubMed ID: 12120035
[TBL] [Abstract][Full Text] [Related]
9. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
10. A comparison of ML Flow serology and slit skin smears to assess the bacterial load in newly diagnosed leprosy patients in Brazil.
Lyon S; Lyon AC; Da Silva RC; Grossi MA; Lyon SH; Bührer-Sékula S; Rocha MO
Lepr Rev; 2008 Jun; 79(2):162-70. PubMed ID: 18711938
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of polymerase chain reaction-based detection of Mycobacterium leprae for the diagnosis of leprosy.
Bang PD; Suzuki K; Phuong le T; Chu TM; Ishii N; Khang TH
J Dermatol; 2009 May; 36(5):269-76. PubMed ID: 19382997
[TBL] [Abstract][Full Text] [Related]
12. Anti-PGL-1 antibody levels in Thai leprosy patients.
Kampirapap K; Singtham N
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):728-33. PubMed ID: 9253875
[TBL] [Abstract][Full Text] [Related]
13. Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.
Barreto JA; Nogueira ME; Diorio SM; Bührer-Sékula S
Rev Soc Bras Med Trop; 2008; 41 Suppl 2():45-7. PubMed ID: 19618075
[TBL] [Abstract][Full Text] [Related]
14. The value of IgM antibodies to PGL-I in the diagnosis of leprosy.
Lefford MJ; Hunegnaw M; Siwik E
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):432-40. PubMed ID: 1890367
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
16. Serum IgA1 and IgM antibodies against Mycobacterium leprae-derived phenolic glycolipid-I: a comparative study in leprosy patients and their contacts.
Chujor CS; Bernheimer H; Levis WR; Schwerer B
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):441-9. PubMed ID: 1890368
[TBL] [Abstract][Full Text] [Related]
17. Detection of M. leprae-specific antigens with dot-ELISA in urine and nasal samples from leprosy patients.
Singh NB; Choudhary A; Bhatnagar S
Int J Lepr Other Mycobact Dis; 1991 Sep; 59(3):398-404. PubMed ID: 1890363
[TBL] [Abstract][Full Text] [Related]
18. Semi-quantitative detection of Mycobacterium leprae antigens in skin scrapings: suitability as a laboratory aid for field diagnosis of leprosy.
Chaturvedi V; Girdhar BK; Sengupta U; Sinha S
Trans R Soc Trop Med Hyg; 2007 Jul; 101(7):699-706. PubMed ID: 17445850
[TBL] [Abstract][Full Text] [Related]
19. A simple dipstick assay for the detection of antibodies to phenolic glycolipid-I of Mycobacterium leprae.
Bührer SS; Smits HL; Gussenhoven GC; van Ingen CW; Klatser PR
Am J Trop Med Hyg; 1998 Feb; 58(2):133-6. PubMed ID: 9502593
[TBL] [Abstract][Full Text] [Related]
20. Performance of recombinant ESAT-6 antigen (ML0049) for detection of leprosy patients.
Parkash O; Pandey R; Kumar A; Kumar A
Lett Appl Microbiol; 2007 May; 44(5):524-30. PubMed ID: 17451520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
